Journal article

Chimeric Antigen Receptor beyond CAR-T Cells

Vicky Mengfei Qin, Criselle D'Souza, Paul J Neeson, Joe Jiang Zhu

Cancers | MDPI | Published : 2021


Chimeric antigen receptors (CAR) are genetically engineered receptors that can recognise specific antigens and subsequently activate downstream signalling. Human T cells engineered to express a CAR, also known as CAR-T cells, can target a specific tumour antigen on the cell surface to mediate a cytotoxic response against the tumour. CAR-T cell therapy has achieved remarkable success in treating hematologic malignancies, but not in solid tumours. Currently, extensive research is being carried out to make CAR-T cells a therapy for solid tumours. To date, most of the research interest in the field has focused on cytotoxic T lymphocytes as the carrier of CAR products. However, in addition to T c..

View full abstract